JP6310164B1 - アセトアミノフェン製剤の製造方法 - Google Patents

アセトアミノフェン製剤の製造方法 Download PDF

Info

Publication number
JP6310164B1
JP6310164B1 JP2017545607A JP2017545607A JP6310164B1 JP 6310164 B1 JP6310164 B1 JP 6310164B1 JP 2017545607 A JP2017545607 A JP 2017545607A JP 2017545607 A JP2017545607 A JP 2017545607A JP 6310164 B1 JP6310164 B1 JP 6310164B1
Authority
JP
Japan
Prior art keywords
acetaminophen
weight
tablet
production method
dispersant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017545607A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2017195796A1 (ja
Inventor
坂本　浩
浩 坂本
邦男 駒居
邦男 駒居
賢司 ▲榊▼原
賢司 ▲榊▼原
宏和 番場
宏和 番場
清 福田
清 福田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Zoki Pharmaceutical Co Ltd
Original Assignee
Nippon Zoki Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Zoki Pharmaceutical Co Ltd filed Critical Nippon Zoki Pharmaceutical Co Ltd
Priority to JP2018048354A priority Critical patent/JP6966780B2/ja
Application granted granted Critical
Publication of JP6310164B1 publication Critical patent/JP6310164B1/ja
Publication of JPWO2017195796A1 publication Critical patent/JPWO2017195796A1/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2017545607A 2016-05-10 2017-05-09 アセトアミノフェン製剤の製造方法 Active JP6310164B1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2018048354A JP6966780B2 (ja) 2016-05-10 2018-03-15 アセトアミノフェン製剤の製造方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP2016094764 2016-05-10
JP2016094764 2016-05-10
JP2016165993 2016-08-26
JP2016165993 2016-08-26
JP2016201560 2016-10-13
JP2016201560 2016-10-13
PCT/JP2017/017603 WO2017195796A1 (ja) 2016-05-10 2017-05-09 アセトアミノフェン製剤の製造方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018048354A Division JP6966780B2 (ja) 2016-05-10 2018-03-15 アセトアミノフェン製剤の製造方法

Publications (2)

Publication Number Publication Date
JP6310164B1 true JP6310164B1 (ja) 2018-04-11
JPWO2017195796A1 JPWO2017195796A1 (ja) 2018-05-24

Family

ID=60266484

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017545607A Active JP6310164B1 (ja) 2016-05-10 2017-05-09 アセトアミノフェン製剤の製造方法
JP2018048354A Active JP6966780B2 (ja) 2016-05-10 2018-03-15 アセトアミノフェン製剤の製造方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018048354A Active JP6966780B2 (ja) 2016-05-10 2018-03-15 アセトアミノフェン製剤の製造方法

Country Status (9)

Country Link
US (2) US11033501B2 (enExample)
EP (1) EP3456324B1 (enExample)
JP (2) JP6310164B1 (enExample)
KR (1) KR102408085B1 (enExample)
CN (1) CN109069455B (enExample)
CA (1) CA3023478C (enExample)
SG (1) SG11201809835UA (enExample)
TW (1) TWI742078B (enExample)
WO (1) WO2017195796A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7105473B2 (ja) * 2017-04-19 2022-07-25 日本臓器製薬株式会社 プレミックス原薬の製造方法
WO2020004393A1 (ja) * 2018-06-26 2020-01-02 日本臓器製薬株式会社 粒子サイズが不揃いな原薬粒子の処理方法
WO2020131795A1 (en) * 2018-12-18 2020-06-25 DDP Specialty Electronic Materials US, Inc. A sustained release composition comprising a hydroxyalkyl methylcellulose
JP7360460B2 (ja) * 2019-06-07 2023-10-12 あゆみ製薬株式会社 口腔内崩壊錠及びその製造方法
CN111920774B (zh) * 2020-08-06 2022-08-12 河北君临药业有限公司 一种对乙酰氨基酚片及其制备方法
CN114432256A (zh) * 2021-12-31 2022-05-06 陕西必康制药集团控股有限公司 对乙酰氨基酚包衣片及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61145111A (ja) * 1984-12-20 1986-07-02 Lion Corp アセトアミノフェン含有錠剤の製造方法
JP2003509368A (ja) * 1999-09-16 2003-03-11 ローディア・インコーポレイテッド 直接圧縮可能な超微粒アセトアミノフェン組成物及びその製造方法
JP2012144520A (ja) * 2010-12-24 2012-08-02 Lion Corp 錠剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5733578A (en) * 1995-11-15 1998-03-31 Edward Mendell Co., Inc. Directly compressible high load acetaminophen formulations
AU2944700A (en) 1999-03-15 2000-10-04 Kaken Pharmaceutical Co., Ltd. Quickly disintegrating tablets and process for producing the same
JP4925526B2 (ja) 2001-09-10 2012-04-25 旭化成ケミカルズ株式会社 薬物の混合方法
US20110268798A1 (en) * 2009-01-16 2011-11-03 Add Advanced Drug Delivery Technologies Ltd Orally disntegrating tablets for the treatment of pain
US20120129878A1 (en) 2009-07-28 2012-05-24 Takeda Pharmaceutical Company Limited Tablet

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61145111A (ja) * 1984-12-20 1986-07-02 Lion Corp アセトアミノフェン含有錠剤の製造方法
JP2003509368A (ja) * 1999-09-16 2003-03-11 ローディア・インコーポレイテッド 直接圧縮可能な超微粒アセトアミノフェン組成物及びその製造方法
JP2012144520A (ja) * 2010-12-24 2012-08-02 Lion Corp 錠剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
医薬品添加物事典 2007, vol. 第1刷, JPN6017047514, 25 July 2007 (2007-07-25), JP, pages 65 - 67, ISSN: 0003700229 *

Also Published As

Publication number Publication date
EP3456324A1 (en) 2019-03-20
US20190142754A1 (en) 2019-05-16
WO2017195796A1 (ja) 2017-11-16
US20210220283A1 (en) 2021-07-22
EP3456324A4 (en) 2019-12-11
TW201808272A (zh) 2018-03-16
CN109069455A (zh) 2018-12-21
TWI742078B (zh) 2021-10-11
CA3023478C (en) 2024-02-06
EP3456324B1 (en) 2023-04-05
SG11201809835UA (en) 2018-12-28
JP2018090638A (ja) 2018-06-14
CA3023478A1 (en) 2017-11-16
JP6966780B2 (ja) 2021-11-17
KR102408085B1 (ko) 2022-06-13
JPWO2017195796A1 (ja) 2018-05-24
KR20190005939A (ko) 2019-01-16
US11433031B2 (en) 2022-09-06
CN109069455B (zh) 2020-10-09
US11033501B2 (en) 2021-06-15

Similar Documents

Publication Publication Date Title
JP6310164B1 (ja) アセトアミノフェン製剤の製造方法
JP6706245B2 (ja) 微結晶性セルロースを含む直接圧縮可能な組成物
US8877249B2 (en) Granular material for dosage forms
JPWO2008149894A1 (ja) セルロース系微小核粒子及びその製造方法
JP7106161B2 (ja) 粒子サイズが不揃いな原薬粒子の処理方法
JP6624662B2 (ja) アセトアミノフェン製剤及びその製造方法
TW202037366A (zh) 纖維素粉末、錠劑及錠劑之製造方法
JP7109255B2 (ja) 粉砕物の製造方法及び錠剤の製造方法
JP7105473B2 (ja) プレミックス原薬の製造方法
US20160022661A1 (en) Dosage Form Comprising Crizotinib
EP3072529B1 (en) Composition comprising vemurafenib and hpmc-as
HK1262022A1 (en) Method for manufacturing acetaminophen preparation
HK1262022B (en) Method for manufacturing acetaminophen preparation
WO2016151067A1 (en) Composition comprising vemurafenib and cationic copolymer based on methacrylates

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171011

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171011

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20171101

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20171122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180129

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180216

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180315

R150 Certificate of patent or registration of utility model

Ref document number: 6310164

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250